Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1935-1946

  Blumsohn, A ^a   Marin, F ^b   Nickelsen, T ^b   Brixen, K ^c   Sigurdsson, G ^d   De La Vera, J González ^e   Boonen, S ^f   Liu Leage S ^b   Barker, C ^b   Eastell, R ^g  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c Universitethospital ^*  (Denmark)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

BMD; Bone markers; Bone turnover; Osteoporosis; Postmenopausal women; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE TURNOVER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEMUR NECK; HIP; HORMONAL THERAPY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSSIFICATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; TREATMENT RESPONSE;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG SUBSTITUTION; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSPECTIVE STUDIES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 79955987629     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1379-y     Document Type: Conference Paper

References (40)

1. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert I, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846-1853 (Pubitemid 32911491)
2. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941 (Pubitemid 37377441)
3. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855-864 (Pubitemid 43787992)
4. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH (1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502 (Pubitemid 47457425)
5. Keaveny TM, Donley D, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 21:149-157 (Pubitemid 46032608)
6. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543 (Pubitemid 36241071)
7. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH (2004) Teriparatide [PTH (1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623-629 (Pubitemid 41071223)
8. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948-958 (Pubitemid 40797995)
9. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
10. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide compared with alendronate for the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039 (Pubitemid 350106710)
11. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768 (Pubitemid 41138965)
12. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916
13. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970 (Pubitemid 40712820)
14. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L-G, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970-3977 (Pubitemid 41058159)
15. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezkian JP, Rosen CJ, for the PaTH Study Investigators (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215 (Pubitemid 37152030)
16. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
17. Finkelstein JS, Leder BZ, Burnett SA, Wyland JJ, Lee H, de la Paz V, Gibson K, Neer RM (2006) Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882-2887 (Pubitemid 44271730)
18. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-575 (Pubitemid 41138938)
19. Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772-3780
20. Seibel MJ (2005) Biochemical markers of bone turnover. Part 1: biochemistry and variability. Clin Biochem Rev 26:97-122
21. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591-1600
22. Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Melo-Gomes J, Obermayer-Pietsch BM, Avramidis A, Sigurdsson G, Glüer C-C (2009) Sequential treatment of severe postmenopausal osteoporosis following teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726-736
23. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Glueer CC, Zysset PK (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS Study. J Bone Miner Res 24:1672-1680
24. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC (2010) Quantitative computed tomography assessment of the effects of 24 months of teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: results from the EURO-FORS study. J Bone Miner Res 25:472-481. doi:10.1359/JBMR.090820
25. Genant HK, Grampp S, Glüer CC, Faulkner KG, Jergas M, Hagiwara S, van Kuijk C (1994) Universal standardisation for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 9:1503-1514 (Pubitemid 24300099)
26. Hanson J (1997) Standardization of femur bone mineral density. J Bone Miner Res 12:1316-1317
27. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C, Glüer C-C, for the EUROFORS High Resolution Quantitative Computed Tomography Substudy Group (2007) Monitoring teriparatide associated changes in vertebral microstructure by high-resolution computed tomography in vivo: results from the EUROFORS study. J Bone Miner Res 22:1426-1433 (Pubitemid 351339687)
28. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860 (Pubitemid 351398563)
29. Bauer DC, Garnero P, Bilezikian JP, Greenspon SL, Ensrud KE, Rosen CJ, Palermo L, Black DM, for the PTH and Alendronate (PaTH) Research Group (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370-1375
30. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, for the PaTH Study Investigators (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565 (Pubitemid 41138937)
31. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, for the Treatment of Osteoporosis with Parathyroid Hormone Study Group (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326-339 (Pubitemid 351650593)
32. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induce spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434-442 (Pubitemid 30450127)
33. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17 (Pubitemid 36008334)
34. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226 (Pubitemid 37152031)
35. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785-3793
36. Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I (2009) Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 24:1998-2006
37. Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalska D, Pavo I (2010) Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int. doi:10.1007/s00198-009-1168-7
38. Lindsay R, Cosman F, Zhou H, Nieves JW, Bostrom M, Barbuto N, Dempster DW (2007) Prior alendronate treatment does not inhibit the early stimulation of osteoblast activity in response to teriparatide. J Bone Miner Res 22(Suppl):S124, Abstract.
39. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66 (Pubitemid 43106908)
40. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19:529-535